The researchers stated, "because of the recent implications of toxin producing fungi with 'Sick-Building-Syndrome', ways of treating contaminated indoor environments, as well as preventing the contamination of indoor environments, has become a major concern. Treating drywall with a fungistatic compound such as Sporicidin before installation of the drywall may be a more effective means of reducing the hazards of indoor microbial contamination than eradication of mold growth after the homes/buildings have been occupied."
Sporicidin, an EPA registered hospital disinfectant, was developed by Sporicidin International of Rockville, Maryland. Dr. Robert Schattner, President of Sporicidin International, also developed Chloraseptic Mouthwash. A copy of the study, which has been submitted for publication, is available on request.